ABVC BioPharma(ABVC) - 2024 Q2 - Quarterly Results

Exhibit 99.1 ABVC BioPharma Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements ● Executed Global Licensing Agreements that could provide up to $292 million in income ● Received Cash Milestone Incomes of $116,000 ● Achieved Significant Improvements in Earnings ● Obtained Multiple Patents and FDA Approvals Fremont, CA (August 15, 2024) – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophtha ...